Luis Marquez, MD
Family Medicine · San Diego, CANPI 1801865795
Payments from drug & device makers
Across 536 payments — averaging $24.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$2K
- Novo Nordisk$1K
- Novartis$845
- Lilly USA, LLC$842
- Amgen$670
- plus $6K from 33 others
What the payments were for
- Travel & lodging$110%
- Food & beverage$12,983100%
- Education$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 80 | $1,737 |
| AstraZeneca | 58 | $1,695 |
| Novo Nordisk | 45 | $1,075 |
| Novartis | 36 | $845 |
| Lilly USA, LLC | 30 | $842 |
| Amgen | 17 | $670 |
| Amarin Pharma, Inc. | 21 | $584 |
| Boehringer Ingelheim | 27 | $565 |
| Sanofi-aventis U.S. LLC | 24 | $510 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 20 | $398 |
| GSK | 11 | $395 |
| Astellas Pharma US Inc | 21 | $346 |
| Merck | 13 | $344 |
| Johnson & Johnson | 26 | $301 |
| Daiichi Sankyo Inc. | 6 | $295 |
| Boston Scientific | 6 | $268 |
| Kowa Pharmaceuticals America, Inc. | 14 | $258 |
| Bayer | 7 | $249 |
| Mannkind Corporation | 7 | $231 |
| Theratechnologies Inc. | 9 | $199 |
| Radius Health, Inc. | 7 | $164 |
| Pfizer | 7 | $135 |
| Biotronik Inc. | 3 | $133 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $129 |
| Arbor Pharmaceuticals, Inc. | 5 | $94 |
| Gilead | 4 | $82 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $64 |
| OPKO Pharmaceuticals, LLC | 1 | $58 |
| Dexcom, Inc. | 3 | $53 |
| Nevro Corp. | 3 | $53 |
| Esperion Therapeutics, Inc. | 3 | $47 |
| Sunovion Pharmaceuticals Inc. | 3 | $39 |
| E.r. Squibb & Sons, L.L.C. | 2 | $36 |
| Biohaven Pharmaceuticals, Inc. | 1 | $24 |
| Abbott | 1 | $22 |
| Eisai Inc. | 1 | $21 |
| Pulmonx Corporation | 1 | $20 |
| Seqirus USA Inc | 1 | $16 |
| Topcon Healthcare Solutions, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$367
- FARXIGA$359
- BREZTRI$250
- Ozempic$243
- TRELEGY ELLIPTA$243
- AIRSUPRA$242
- Vascepa$240
- ENTRESTO$238
- MOUNJARO$230
- INJECTAFER$215
- GENERAL PAIN MANAGEMENT$158
- AFREZZA$125
- QULIPTA$125
- Prolia$123
- STEGLATRO$123
- Kerendia$123
- BOTOX COSMETIC$122
- Repatha$122
- Saxenda$122
- RYBELSUS$120
How this compares
$13,012 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 136 | $177,028 |
| OzempicSemaglutide | 148 | $152,418 |
| FarxigaDapagliflozin Propanediol | 76 | $66,999 |
| EliquisApixaban | 48 | $62,496 |
| TrulicityDulaglutide | 44 | $58,671 |
| LinzessLinaclotide | 62 | $47,232 |
| RybelsusSemaglutide | 14 | $29,476 |
| JanuviaSitagliptin Phosphate | 19 | $27,983 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $21,508 |
| MounjaroTirzepatide | 22 | $21,132 |
| TradjentaLinagliptin | 29 | $20,843 |
| EntrestoSacubitril/Valsartan | 12 | $18,133 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $12,466 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $11,559 |
| Atorvastatin Calcium | 876 | $10,840 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $565 | $197,871165 claims |
| Novo NordiskOzempic, Rybelsus | $1,075 | $181,894162 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $842 | $79,80366 claims |
| AstraZenecaFarxiga | $1,695 | $66,99976 claims |
| PfizerEliquis | $135 | $62,49648 claims |
| AbbVieLinzess | $1,737 | $47,23262 claims |
| MerckJanuvia, Dulera | $344 | $33,77335 claims |
| NovartisEntresto | $845 | $18,13312 claims |
| GSKTrelegy Ellipta | $395 | $12,46613 claims |
| Astellas Pharma US IncMyrbetriq | $346 | $7,63812 claims |
| Sanofi-aventis U.S. LLCLantus | $510 | $2,39514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.
Other family medicine in San Diego
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Laurie Han-ConradSan Diego$2.9M
- Sheldon MorrisSan Diego$1.1M
- Mirwais SaifiSan Diego$1M
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.